Cancer Genome Profiling

TSO 500 HT Assay

TruSight Oncology 500 High-Throughput Assay (TSO 500 HT) is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. The TSO 500 HT assay can not only support the comprehensive genome analysis of FFPE samples, but also provide the flexibility of maximum 192 samples/flow cell. This product supports identification of all relevant DNA and RNA variants implicated in various solid tumor types, alone with the measurement of microsatellite instability (MSI) and tumor mutational burden (TMB).

Consolidate Multiple Biomarker Assays into One

Pan-cancer biomarker content aligned with key guidelines and clinical trials
DNA + RNA assay targeting 523 genes for assessment of all DNA and RNA variant types, plus MSI and TMB
Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay

Streamlined Sample-to-Results Workflow

Go from initial sample to results in 4-5 days
Automation kits and methods available for reduced hands-on time and scalability
Easily translate raw data into a final interpretation report, powered by PierianDx Clinical Genomics Workspace (CGW) software.

https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-500.html

TSO 500 ctDNA Assay

TruSight Oncology ctDNA is a pan-cancer next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling (CGP) from blood plasma.

The broad panel is designed with similar DNA content as its tissue counterparts (TruSight Oncology 500 and TruSight Oncology 500 High-Throughput), including key immuno-oncology (IO) biomarkers, making it ideal to utilize in conjunction with or without precious tissue samples.

Enable Comprehensive Genomic Profiling from Plasma

Pan-cancer CGP assay aligned with key guidelines and trials
Similar DNA content as TruSight Oncology 500, including full coding sequence of 523 genes
Detects single nucleotide variants (SNVs), Indels, CNVs, fusions, and IO biomarkers

Implement In-house CGP with an Integrated Workflow

Streamlined 5-day workflow from cfDNA results
Rapid variant calling algorithm powered by DRAGEN Analysis Software and the DRAGEN Server v3
Integrated interpretation report available through Clinical Genomics Workspace from Pierian Dx

https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-500-ctdna.html

我對這服務有興趣

Taiwan Genomic Industry Alliance Inc. (TGIA)

886-2-2651-7187
3F., No. 451, Chongyang Rd., Nangang Dist., Taipei City 115 , Taiwan (R.O.C.)
service@tgiainc.com
09:00AM ~ 06:00PM